# OGN

## Overview
The OGN gene encodes osteoglycin, a small leucine-rich proteoglycan (SLRP) that plays a crucial role in the regulation of collagen fibrillogenesis and extracellular matrix organization. Osteoglycin is characterized by its leucine-rich repeat (LRR) domains, which contribute to its structural stability and function. As a proteoglycan, osteoglycin is involved in various biological processes, including bone metabolism, glucose homeostasis, and cellular signaling pathways. It interacts with key receptors such as VEGFR2 and EGFR, influencing angiogenesis and cancer progression. Clinically, alterations in OGN expression have been linked to diseases such as heart failure and cancer, where it may serve as a biomarker or therapeutic target (Tanaka2012Role; Zhu2024Identifying; Ge2004Bone; Wu2016Loss).

## Structure
Osteoglycin (OGN) is a small leucine-rich proteoglycan (SLRP) characterized by a core protein with leucine-rich repeat (LRR) domains. The primary structure of OGN includes a signal peptide, six cysteine residues, and six LRRs, which are typical of class III SLRPs (Ge2004Bone). The secondary structure is organized into beta-sheets that form a horseshoe shape, a common feature of LRR proteins (Costa2018Vertebrate). The LRRs are organized into four super-repeats, similar to mammalian class III proteoglycans, and are flanked by conserved cysteine clusters that likely form disulfide bridges, contributing to the protein's stability (Costa2018Vertebrate).

Post-translational modifications of OGN include glycosylation, as evidenced by the presence of N-linked high mannose oligosaccharides in recombinant OGN (Ge2004Bone). OGN is also processed by bone morphogenetic protein-1 (BMP-1) and related metalloproteinases, which cleave the N-prodomain to produce a mature form that enhances its ability to regulate collagen fibrillogenesis (Ge2004Bone). The protein can exist in multiple isoforms due to alternative splicing, which may affect its function and localization (Iozzo2015Proteoglycan).

## Function
Osteoglycin (OGN) is a small leucine-rich proteoglycan that plays a significant role in collagen fibrillogenesis and extracellular matrix organization. It is involved in the regulation of collagen fiber formation, which is crucial for maintaining the structural integrity of tissues such as bone and the cornea. OGN undergoes proteolytic processing by bone morphogenetic protein-1 (BMP-1) and Tolloid-like proteinases, converting it from a precursor to a mature form that is more effective in inhibiting collagen fibrillogenesis (Ge2004Bone).

In bone metabolism, OGN is expressed in osteoblasts, where it influences their differentiation and function. It suppresses differentiation in premature osteoblasts while enhancing the osteoblast phenotype and mineralization in well-differentiated cells (Tanaka2012Role). OGN also interacts with TGF-β, enhancing collagen production and transcriptional activity in osteoblastic cells (Tanaka2012Role).

OGN is also involved in glucose metabolism and insulin action. It is expressed in various tissues, including bone, muscle, and adipose tissue, and plays a role in improving glucose tolerance and insulin sensitivity. Osteoglycin-deficient mice exhibit impaired glucose tolerance and insulin resistance, highlighting its importance in glucose homeostasis (Lee2018Osteoglycin).

## Clinical Significance
The OGN gene, encoding osteoglycin, has been implicated in several diseases due to alterations in its expression levels and interactions. In heart failure (HF), OGN is identified as a potential biomarker due to its high expression in the plasma of HF patients. It is involved in pathways affecting cardiac function, particularly through immune-related pathways and extracellular matrix interactions, contributing to cardiac dysfunction and adverse remodeling post-myocardial infarction (Zhu2024Identifying). Genetic data suggest a causal relationship between elevated plasma OGN levels and increased HF risk, highlighting its potential as a diagnostic biomarker (Zhu2024Identifying).

In cancer, OGN plays a role in meningioma development by downregulating the NF2 tumor suppressor gene and activating the mTOR signaling pathway, promoting tumor growth (Mei2017Osteoglycin). In bladder cancer, OGN acts as a tumor suppressor, with its expression being upregulated by ECRG4, which inhibits the NF-κB signaling pathway, reducing cell proliferation and invasiveness (Liang2020ECRG4). These findings suggest that OGN's dysregulation can significantly impact disease progression, making it a potential target for therapeutic interventions.

## Interactions
Osteoglycin (OGN) is known to interact with various proteins, influencing several cellular processes. OGN physically associates with the vascular endothelial growth factor receptor 2 (VEGFR2) in human umbilical vein endothelial cells (HUVECs) and mouse skeletal muscle samples. This interaction negatively modulates the binding of vascular endothelial growth factor (VEGF) to VEGFR2, suggesting that OGN competes with VEGF for binding to VEGFR2, thereby inhibiting VEGF-VEGFR2 signaling (Wu2016Loss). OGN's interaction with VEGFR2 is distinct from other small leucine-rich proteoglycans like decorin, as OGN lacks the specific amino acid sequence found in decorin that binds to VEGFR2. Molecular docking analysis has shown that OGN forms hydrogen bonds with specific residues of VEGFR2, supporting a direct interaction (Wu2016Loss).

In the context of colorectal cancer, OGN interacts with the epidermal growth factor receptor (EGFR), increasing its dimerization and leading to endocytosis. This interaction recruits downstream components like Eps15 and epsin1, which are involved in the EGFR internalization machinery, ultimately affecting the EGFR/AKT/Zeb-1 signaling pathway (Hu2018Osteoglycin). These interactions highlight OGN's role in modulating key signaling pathways involved in angiogenesis and cancer progression.


## References


[1. (Iozzo2015Proteoglycan) Renato V. Iozzo and Liliana Schaefer. Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biology, 42:11–55, March 2015. URL: http://dx.doi.org/10.1016/j.matbio.2015.02.003, doi:10.1016/j.matbio.2015.02.003. This article has 881 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.matbio.2015.02.003)

[2. (Lee2018Osteoglycin) N.J. Lee, N. Ali, L. Zhang, Y. Qi, I. Clarke, R.F. Enriquez, M. Brzozowska, I.C. Lee, M.J. Rogers, D.R. Laybutt, J.R. Center, P.A. Baldock, and H. Herzog. Osteoglycin, a novel coordinator of bone and glucose homeostasis. Molecular Metabolism, 13:30–44, July 2018. URL: http://dx.doi.org/10.1016/j.molmet.2018.05.004, doi:10.1016/j.molmet.2018.05.004. This article has 47 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.molmet.2018.05.004)

[3. (Ge2004Bone) Gaoxiang Ge, Neung-Seon Seo, Xiaowen Liang, Delana R. Hopkins, Magnus Höök, and Daniel S. Greenspan. Bone morphogenetic protein-1/tolloid-related metalloproteinases process osteoglycin and enhance its ability to regulate collagen fibrillogenesis. Journal of Biological Chemistry, 279(40):41626–41633, October 2004. URL: http://dx.doi.org/10.1074/jbc.m406630200, doi:10.1074/jbc.m406630200. This article has 82 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m406630200)

[4. (Wu2016Loss) Qi-Hong Wu, Yu Ma, Cheng-Chao Ruan, Yan Yang, Xin-He Liu, Qian Ge, Ling-Ran Kong, Ji-Wei Zhang, Chen Yan, and Ping-Jin Gao. Loss of osteoglycin promotes angiogenesis in limb ischaemia mouse models via modulation of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 signalling pathway. Cardiovascular Research, 113(1):70–80, October 2016. URL: http://dx.doi.org/10.1093/cvr/cvw220, doi:10.1093/cvr/cvw220. This article has 18 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/cvr/cvw220)

[5. (Tanaka2012Role) Ken-ichiro Tanaka, Erika Matsumoto, Yoshiko Higashimaki, Takenobu Katagiri, Toshitsugu Sugimoto, Susumu Seino, and Hiroshi Kaji. Role of osteoglycin in the linkage between muscle and bone. Journal of Biological Chemistry, 287(15):11616–11628, April 2012. URL: http://dx.doi.org/10.1074/jbc.m111.292193, doi:10.1074/jbc.m111.292193. This article has 97 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m111.292193)

[6. (Mei2017Osteoglycin) Yu Mei, Ziming Du, Changchen Hu, Noah F. Greenwald, Malak Abedalthagafi, Nathalie Y.R. Agar, Gavin P. Dunn, Wenya Linda Bi, Sandro Santagata, and Ian F. Dunn. Osteoglycin promotes meningioma development through downregulation of nf2 and activation of mtor signaling. Cell Communication and Signaling, September 2017. URL: http://dx.doi.org/10.1186/s12964-017-0189-7, doi:10.1186/s12964-017-0189-7. This article has 20 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12964-017-0189-7)

[7. (Zhu2024Identifying) Yihao Zhu, Bin Chen, and Yao Zu. Identifying ogn as a biomarker covering multiple pathogenic pathways for diagnosing heart failure: from machine learning to mechanism interpretation. Biomolecules, 14(2):179, February 2024. URL: http://dx.doi.org/10.3390/biom14020179, doi:10.3390/biom14020179. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/biom14020179)

[8. (Hu2018Osteoglycin) Xiang Hu, Ya-Qi Li, Qing-Guo Li, Yan-Lei Ma, Jun-Jie Peng, and San-Jun Cai. Osteoglycin (ogn) reverses epithelial to mesenchymal transition and invasiveness in colorectal cancer via egfr/akt pathway. Journal of Experimental &amp; Clinical Cancer Research, March 2018. URL: http://dx.doi.org/10.1186/s13046-018-0718-2, doi:10.1186/s13046-018-0718-2. This article has 40 citations.](https://doi.org/10.1186/s13046-018-0718-2)

[9. (Costa2018Vertebrate) R. A. Costa, R. S. T. Martins, E. Capilla, L. Anjos, and D. M. Power. Vertebrate slrp family evolution and the subfunctionalization of osteoglycin gene duplicates in teleost fish. BMC Evolutionary Biology, December 2018. URL: http://dx.doi.org/10.1186/s12862-018-1310-2, doi:10.1186/s12862-018-1310-2. This article has 2 citations.](https://doi.org/10.1186/s12862-018-1310-2)

[10. (Liang2020ECRG4) Xin Liang, Jiangang Gao, Quan Wang, Sichuan Hou, and Changli Wu. Ecrg4 represses cell proliferation and invasiveness via nfic/ogn/nf-κb signaling pathway in bladder cancer. Frontiers in Genetics, August 2020. URL: http://dx.doi.org/10.3389/fgene.2020.00846, doi:10.3389/fgene.2020.00846. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2020.00846)